Related Experiment Videos
Therapy for hepatic fibrosis
1Department of Medicine, University of California, San Diego.
Abstract:
Although there is no established therapy for the fibrogenesis of hepatic cirrhosis, many potential therapies are now emerging. The requirements for the "perfect therapy" for hepatic fibrosis can be listed: (1) the pharmacologic agent should be active only in the liver; (2) its effect should be specific for collagen (or another critical extracellular matrix component); and (3) it should not be toxic. To date no agents fulfill these criteria. Of the agents we reviewed, only colchicine appears sufficiently safe for use outside of controlled clinical trials for cirrhotic patients whose underlying disease is not otherwise treatable. However, confirmation of the efficacy of colchicine in additional well-controlled clinical trials is still required. Agents such as collagen propeptides require extensive in vitro development, while trials in animal models are required for prolyl 4-hydroxylase inhibitors, proline analogues, and prostaglandins. For more developed agents, such as malotilate and gamma-interferon, there is now a need for well-designed long-term clinical trials.
Insights
No perfect therapy exists for liver fibrosis, but emerging treatments show promise. Colchicine is the safest option for untreatable cirrhosis, though more clinical trials are needed for confirmation.
Area of Science:
- Hepatology
- Fibrosis Research
- Pharmacology
Background:
- Hepatic cirrhosis fibrogenesis lacks established therapies.
- Ideal antifibrotic agents must be liver-specific, target extracellular matrix, and be non-toxic.
- Current therapeutic options do not meet these ideal criteria.
Purpose of the Study:
- To review emerging therapies for hepatic fibrosis.
- To evaluate the safety and efficacy of potential antifibrotic agents.
- To identify the most promising therapeutic strategies for clinical development.
Main Methods:
- Literature review of potential antifibrotic agents.
- Assessment of agent specificity, liver-targeting capabilities, and toxicity profiles.
- Evaluation of the developmental stage of various therapeutic candidates.
Main Results:
- No single agent currently meets all criteria for a perfect antifibrotic therapy.
- Colchicine demonstrates acceptable safety for use in specific patient populations, pending further trials.
- Other agents like collagen propeptides, prolyl 4-hydroxylase inhibitors, proline analogues, prostaglandins, malotilate, and gamma-interferon require further development or clinical validation.
Conclusions:
- Colchicine is a potential candidate for managing untreatable hepatic cirrhosis, but requires more clinical trial validation.
- Significant further research and development are necessary for other promising antifibrotic agents.
- The development of effective therapies for hepatic fibrosis remains an ongoing challenge requiring rigorous investigation.